In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $408.85, marking a +1.15% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.06%. Elsewhere, the Dow ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $381.87, denoting a +1.39% move from the preceding trading day.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Investors with significant funds have taken a bearish position in Vertex Pharmaceuticals (NASDAQ:VRTX), a development that retail traders should be aware of. This was brought to our attention today ...

Vertex Pharmaceuticals Inc. closed 22.25% short of its 52-week high of $519.88, which the company reached on November 8th.

On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the ...

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vertex secured FDA approval for JOURNAVX, a non-opioid pain treatment, marking a significant advancement in pain management. The company reached a reimbursement agreement with NHS England for CASGEVY, ...

With crypto trading activity picking up on Arbitrum, a new protocol called Vertex is setting its sights on the institutional clientele seeking to trade on decentralized exchanges (DEX) atop the ...

Vertex VERX shares are trading higher on Wednesday after the company reported better-than-expected Q4 results. Vertex reported quarterly earnings of $0.08 per share which beat the analyst consensus ...